We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+4.14%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
-$34.3M
(-25%)
Cap. Flow
-$33.3M
Cap. Flow
% of AUM
-33.2%
Top 10 Holdings %
Top 10 Hldgs %
26.12%
Holding
294
New
64
Increased
32
Reduced
107
Closed
85
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$5.08M |
| 2 |
UnitedHealth
UNH
|
+$4.05M |
| 3 |
Johnson & Johnson
JNJ
|
+$2.82M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$2.52M |
| 5 |
AbbVie
ABBV
|
+$2.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rithm Capital
RITM
|
+$4.32M |
| 2 |
Harmony Biosciences
HRMY
|
+$3.88M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$3.12M |
| 4 |
EFC
Ellington Financial
EFC
|
+$2.6M |
| 5 |
MGIC Investment
MTG
|
+$2.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.58% |
| 2 | Real Estate | 7.4% |
| 3 | Industrials | 5.96% |
| 4 | Financials | 5.87% |
| 5 | Technology | 4.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$1.04T
| $4.74M | 4.73% |
+6,140
| New | +$5.08M |
|
|
2
UnitedHealth
UNH
$384B
| $3.6M | 3.6% |
+7,123
| New | +$4.05M |
|
|
3
Johnson & Johnson
JNJ
$602B
| $2.63M | 2.62% |
+18,176
| New | +$2.82M |
|
4
iShares 1-3 Year Treasury Bond ETF
SHY
$25.7B
| $2.39M | 2.39% |
29,172
+24,690
| +551% | +$2.03M |
|
|
5
AbbVie
ABBV
$449B
| $2.31M | 2.31% |
+13,018
| New | +$2.39M |
|
6
Merck
MRK
$315B
| $2.25M | 2.24% |
22,597
-1,403
| -6% | -$145K |
|
7
Thermo Fisher Scientific
TMO
$202B
| $2.17M | 2.17% |
+4,175
| New | +$2.3M |
|
8
AstraZeneca
AZN
$263B
| $2.08M | 2.07% |
+15,843
| New | +$2.22M |
|
|
NVO
9
Novo Nordisk
NVO
$228B
| $2.01M | 2% |
+23,334
| New | +$2.52M |
|
10
Globus Medical
GMED
$11B
| $2M | 2% |
+24,176
| New | +$1.91M |
|
11
Invesco S&P 500 Pure Value ETF
RPV
$1.58B
| $1.99M | 1.99% |
+22,102
| New | +$2.03M |
|
12
iShares Russell 1000 Value ETF
IWD
$81.9B
| $1.98M | 1.98% |
+10,710
| New | +$2.05M |
|
13
Intuitive Surgical
ISRG
$142B
| $1.93M | 1.93% |
3,706
+2,456
| +196% | +$1.28M |
|
14
Lamar Advertising Co
LAMR
$16.5B
| $1.83M | 1.82% |
+15,000
| New | +$1.96M |
|
15
Boston Scientific
BSX
$66.3B
| $1.67M | 1.66% |
+18,667
| New | +$1.64M |
|
|
PINE
16
Alpine Income Property Trust
PINE
$350M
| $1.54M | 1.54% |
+91,980
| New | +$1.61M |
|
17
Novartis
NVS
$291B
| $1.53M | 1.53% |
+15,719
| New | +$1.68M |
|
18
iShares Global REIT ETF
REET
$5.05B
| $1.44M | 1.44% |
+60,000
| New | +$1.53M |
|
19
Stereotaxis
STXS
$164M
| $1.37M | 1.37% |
600,000
| – | – |
|
20
iShares 3-7 Year Treasury Bond ETF
IEI
$18.2B
| $1.34M | 1.34% |
11,636
+8,510
| +272% | +$993K |
|
21
Vertex Pharmaceuticals
VRTX
$123B
| $1.25M | 1.25% |
+3,101
| New | +$1.44M |
|
22
FLEX LNG
FLNG
$1.69B
| $1.2M | 1.2% |
+52,228
| New | +$1.27M |
|
|
BFS
23
Saul Centers
BFS
$898M
| $1.16M | 1.16% |
+30,000
| New | +$1.2M |
|
24
Bristol-Myers Squibb
BMY
$124B
| $1.11M | 1.11% |
+19,649
| New | +$1.1M |
|
25
SoundHound AI
SOUN
$2.75B
| $1.09M | 1.09% |
55,000
-70,000
| -56% | -$674K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, AlphaCentric Advisors held 294 positions worth $100M, down 25% from $135M the previous quarter. Its ten largest holdings account for 26% of the portfolio.
AlphaCentric Advisors withdrew a net $33.3M in Q4 2024, closing 85 positions and reducing 107 holdings. Its most notable exit was Rithm Capital, an estimated $4.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 58% a quarter earlier, followed by Real Estate and Industrials.
Against the trend, AlphaCentric Advisors opened a new position in Eli Lilly worth $4.74M.
- AlphaCentric Advisors's largest Q4 2024 buy was Eli Lilly: 6,140 shares worth $4.74M.
- AlphaCentric Advisors added most to iShares 1-3 Year Treasury Bond ETF in Q4 2024, an estimated $2.03M increase.
- AlphaCentric Advisors's biggest Q4 2024 reduction was Neurocrine Biosciences, cutting an estimated $2.33M.
- AlphaCentric Advisors fully exited Rithm Capital in Q4 2024, selling an estimated $4.32M.
- AlphaCentric Advisors's ten largest holdings make up 26% of its $100M portfolio in Q4 2024.
- AlphaCentric Advisors opened 64 new positions and closed 85 in Q4 2024.
- AlphaCentric Advisors's portfolio value fell 25% quarter-over-quarter to $100M.
Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.